Codexis Inc
(NAS:CDXS)
$
1.51
-0.085 (-5.33%)
Market Cap: 165.35 Mil
Enterprise Value: 183.02 Mil
PE Ratio: 0
PB Ratio: 4.19
GF Score: 57/100 Codexis Inc at UBS Global Life Science Conference (Virtual) Transcript
May 23, 2022 / 08:15PM GMT
Release Date Price:
$10.51
(+0.19%)
John Newton Sourbeer
UBS Investment Bank, Research Division - Equity Research Associate
Hi. I'm John Sourbeer, UBS' life science tools and pharma services analyst. Welcome to the last panel of the day, of day 1 of the UBS Healthcare Conference. We have -- we're hosting Codexis for this fireside chat, and we have John Nicols, President and CEO.
John J. Nicols
Codexis, Inc. - President, CEO & Director
Pleasure to be here. Thanks.
Questions & Answers
John Newton Sourbeer
UBS Investment Bank, Research Division - Equity Research Associate
Just to get things started, can you provide an overview of Codexis' business model and the different spaces you're involved in as a company? How did you get here? And where do you want to go in the future?
John J. Nicols
Codexis, Inc. - President, CEO & Director
Awesome. Yes, pleasure. So Codexis, we're a 20-year-old company. We've been focused our entire history on enzymes as a class of products to discover and
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot